NVCR Stock Gains After Novocure Announces Positive Topline Results In Metastatic Pancreatic Cancer Therapy Trial
Novocure stated that PANOVA-4 met its pre-specified primary endpoint in the Phase 2 trial, achieving a statistically significant improvement in disease control rate.